Call for Industry Advisory Board Participants
Amgen, Bristol-Myers Squibb, Genentech, Lilly Oncology, and Takeda Oncology, HOPA's Premier level Industry Relations Council participants, would like to invite qualified HOPA members to participate in advisory board meetings to be held just prior to and following the upcoming 11th Annual Conference in Austin, TX. The advisory board meetings will take place Tuesday, March 24, Saturday, March 28, and Sunday, March 29, 2015. Interested members can apply directly in the Volunteer Activity Center
by selecting the advisory board that reflects your interest and qualifications and uploading a CV. The deadline to apply is Monday, December 15
Board of Directors Election
: Vote Now
or preview the candidate profiles
prior to voting. Voting will close December 1 at 11:59 pm CT. Due to VoteNet site maintenance, the ballot will be unavailable on Sunday, November 30 from 12:01 am to 6 am EST.
Please note : For the two At-Large positions, one position shall serve a three-year term and one position shall serve two consecutive one-year terms. The candidate with the highest number of votes shall serve in the At-Large position for a three-year term for 2015-2018; the candidate with the second highest number of votes shall serve in the At-Large position for two consecutive one-year terms for 2015-2017.
HOPA Volunteer Opportunity – BCOP Recertification Education RFP Task Force
HOPA is seeking qualified members for an upcoming task force focused on future BCOP recertification programs. This task force will be charged with designing and developing HOPA’s plan for a future comprehensive BCOP recertification education program. Visit the Volunteer Activity Center
for complete information and to express your interest.
HOPA Oncology Pharmacists: Committed to the Care of Patients with Cancer
Check out the new educational video produced by HOPA
explaining the critical role of the oncology pharmacist.
HOPA’s letter to Genentech CEO Ian Clark has generated a number of references in media coverage on the new distribution model. Here are two of the most recent:
Ascension Health Bans Genentech Sales Reps After Losing Drug Discounts
(PharmTech.com) Oct 7, 2014 - A change in the supply chain for three important Genentech cancer medications elicits a strong reaction from one of the nation's largest operators of hospitals. read article
Genentech Sales Reps Face Hospital Bans Over a Wholesale Change
(Wall Street Journal-Pharmalot) October 3, 2014 - Ascension Health, which is one of the nation’s largest operators of hospitals and clinics, has banned Genentech sales representatives from visiting its 1,900 hospitals and clinics around the country after the drug maker changed distribution for three big-selling cancer medicines earlier this week. read article
The HOPA Board of Directors submitted a letter to Genentech’s CEO Ian T. Clark, addressing the impact that a new distribution model will have on cancer care. Additionally, HOPA, ACCC and other organizations sent a joint letter outlining their concerns.
HOPA has been involved in conversations with Genentech in response to their change in distribution channels for its infused cancer medicines. HOPA continues to closely monitor the situation and provide additional information as it becomes available. If you have specific reports of interruptions in patient care, please contact HOPA at email@example.com with the subject line “Genentech”.
Read Genentechs response to concerns raised by HOPA.
The call for Trainee Research-In-Progress Poster Abstracts for the 2015 HOPA Annual Conference is now open.